



NOVEMBER 16, 2023

# Child and Adolescent Immunization Schedule by Age (Addendum updated June 27, 2024)

Recommendations for Ages 18 Years or Younger, United States, 2024

**PURPOSE**

Guide health care providers in determining recommended vaccines for each age group.

## How to use the schedule



[Vaccines in the Child Immunization Schedule](#)

To make vaccination recommendations, healthcare providers should:

1. Determine recommended vaccine by age ([Table 1 – By Age](#))
2. Determine recommended interval for catch-up vaccination ([Table 2 – Catch-up](#))
3. Assess need for additional recommended vaccines by medical condition or other indication ([Table 3 – By Medical Indication](#))
4. Review vaccine types, frequencies, intervals, and considerations for special situations ([Notes](#))
5. Review contraindications and precautions for vaccine types ([Appendix](#))
6. Review new or updated ACIP guidance ([Addendum](#))

 [Get email updates](#)

**Download the Schedule**

- [Print the schedule, color](#) 
- [Print the schedule, black & white](#) 
- [Download the mobile app](#)

[Compliant version of the schedule](#)

## Birth to 15 Months

**Legend**

Range of recommended ages for all children
  Range of recommended ages for catch-up vaccination
  Range of recommended ages for certain high-risk groups
  Recommended vaccination can begin in this age group
  Recommended vaccination based on shared clinical decision-making
  No recommendation/not applicable

**These recommendations must be read with the notes that follow.** For those who fall behind or start late, provide catch-up vaccination at the earliest opportunity as indicated by the green bars. To determine minimum intervals between doses, see the catch-up schedule ([Table 2](#)).

Vaccine and other immunizing agents	Birth	1 mo	2 mos	4 mos	6 mos	9 mos	12 mos	15 mos
<a href="#">Respiratory syncytial virus</a> ⓘ (RSV-mAb [Nirsevimab])	1 dose depending on maternal RSV vaccination status, See <a href="#">notes</a>					1 dose (8 through 19 months), See <a href="#">notes</a>		
<a href="#">Hepatitis B</a> ⓘ (HepB)	1 <sup>st</sup> dose	←2 <sup>nd</sup> dose→			←3 <sup>rd</sup> dose→			
<a href="#">Rotavirus (RV)</a> ⓘ RV1 (2-dose series); RV5 (3-dose series)			1 <sup>st</sup> dose	2 <sup>nd</sup> dose	See <a href="#">notes</a>			
<a href="#">Diphtheria, tetanus, &amp; acellular pertussis</a> ⓘ (DTaP: <7 yrs)			1 <sup>st</sup> dose	2 <sup>nd</sup> dose	3 <sup>rd</sup> dose			←4 <sup>th</sup> dose→

Vaccine and other immunizing agents	Birth	1 mo	2 mos	4 mos	6 mos	9 mos	12 mos	15 mos
<a href="#">Haemophilus influenzae type b (Hib)</a>			1 <sup>st</sup> dose	2 <sup>nd</sup> dose	See <a href="#">notes</a>			←3 <sup>rd</sup> or 4 <sup>th</sup> dose, See <a href="#">notes</a> →
<a href="#">Pneumococcal conjugate (PCV15, PCV20)</a>			1 <sup>st</sup> dose	2 <sup>nd</sup> dose	3 <sup>rd</sup> dose			←4 <sup>th</sup> dose→
<a href="#">Inactivated poliovirus (IPV: &lt;18 yrs)</a>			1 <sup>st</sup> dose	2 <sup>nd</sup> dose	←3 <sup>rd</sup> dose→			
<a href="#">COVID-19 (1vCOV-mRNA, 1vCOV-aPS)</a>					1 or more doses of updated (2023–2024 Formula) vaccine (See <a href="#">notes</a> )			
<a href="#">Influenza (IIV4)</a>					Annual vaccination 1 or 2 doses			
<b>OR</b> <a href="#">Influenza (LAIV4)</a>								
<a href="#">Measles, mumps, rubella (MMR)</a>					See <a href="#">notes</a>			←1 <sup>st</sup> dose→
<a href="#">Varicella (VAR)</a>								←1 <sup>st</sup> dose→
<a href="#">Hepatitis A (HepA)</a>					(See <a href="#">notes</a> )			←2-dose series, See <a href="#">notes</a> →
<a href="#">Tetanus, diphtheria, &amp; acellular pertussis (Tdap: ≥7 yrs)</a>								
<a href="#">Human papillomavirus (HPV)</a>								
<a href="#">Meningococcal (MenACWY-CRM ≥2 mos, MenACWY-TT ≥2years)</a>	See <a href="#">notes</a>							
<a href="#">Meningococcal B (MenB-4C, MenB-FHbp)</a>								
<a href="#">Respiratory syncytial virus vaccine (RSV [Abrysvo])</a>								
<a href="#">Dengue (DEN4CYD: 9-16 yrs)</a>								
<a href="#">Mpox</a>								

## 18 Months to 18 Years

Vaccine and other immunizing agents	18 mos	19-23 mos	2-3 yrs	4-6 yrs	7-10 yrs	11-12 yrs	13-15 yrs	16 yrs	17-18 yrs
<a href="#">Respiratory syncytial virus (RSV-mAb [Nirsevimab])</a>	1 dose (8 through 19 months), See <a href="#">notes</a>								
<a href="#">Hepatitis B (HepB)</a>	←3 <sup>rd</sup> dose→								
<a href="#">Rotavirus (RV) RV1 (2-dose series); RV5 (3-dose series)</a>									
<a href="#">Diphtheria, tetanus, &amp; acellular pertussis (DTaP: &lt;7 yrs)</a>	←4 <sup>th</sup> dose→		5 <sup>th</sup> dose						
<a href="#">Haemophilus influenzae type b (Hib)</a>									
<a href="#">Pneumococcal conjugate (PCV15, PCV20)</a>									
<a href="#">Inactivated poliovirus (IPV: &lt;18 yrs)</a>	←3 <sup>rd</sup> dose→		4 <sup>th</sup> dose						See <a href="#">notes</a>
<a href="#">COVID-19 (1vCOV-mRNA, 1vCOV-aPS)</a>	1 or more doses of updated (2023–2024 Formula) vaccine (See <a href="#">notes</a> )								
<a href="#">Influenza (IIV4)</a>	Annual vaccination 1 or 2 doses					Annual vaccination 1 dose only			
<b>OR</b> <a href="#">Influenza (LAIV4)</a>				Annual vaccination 1 or 2 doses	<b>OR</b> Annual vaccination 1 dose only				
<a href="#">Measles, mumps, rubella (MMR)</a>				2 <sup>nd</sup> dose					
<a href="#">Varicella (VAR)</a>				2 <sup>nd</sup> dose					
<a href="#">Hepatitis A (HepA)</a>	← 2-dose series, See <a href="#">notes</a> →								
<a href="#">Tetanus, diphtheria, &amp; acellular pertussis (Tdap: ≥7 yrs)</a>						1 dose			

Vaccine and other immunizing agents	18 mos	19-23 mos	2-3 yrs	4-6 yrs	7-10 yrs	11-12 yrs	13-15 yrs	16 yrs	17-18 yrs
<a href="#">Human papillomavirus</a> (HPV) <sup>i</sup>						See <a href="#">notes</a>			
<a href="#">Meningococcal</a> (MenACWY-CRM ≥2 mos, MenACWY-TT ≥2years) <sup>i</sup>		See <a href="#">notes</a>				1 <sup>st</sup> dose		2 <sup>nd</sup> dose	
<a href="#">Meningococcal B</a> (MenB-4C, MenB-FHbp) <sup>i</sup>						See <a href="#">notes</a>			
<a href="#">Respiratory syncytial virus vaccine</a> (RSV [Abrysvo]) <sup>i</sup>						Seasonal administration during pregnancy, See <a href="#">notes</a>			
<a href="#">Dengue</a> (DEN4CYD: 9-16 yrs) <sup>i</sup>						Seropositive in endemic dengue areas (See <a href="#">notes</a> )			
<a href="#">Mpox</a> <sup>i</sup>									

To make vaccination recommendations, healthcare providers should:

1. Determine recommended vaccine by age ([Table 1 - By Age](#))
2. Determine recommended interval for catch-up vaccination ([Table 2 - Catch-up](#))
3. Assess need for additional recommended vaccines by medical condition or other indication ([Table 3 - By Medical Indication](#))
4. Review vaccine types, frequencies, intervals, and considerations for special situations ([Notes](#))
5. Review contraindications and precautions for vaccine types ([Appendix](#))
6. Review new or updated ACIP guidance ([Addendum](#))

## Additional Information

Recommended by the Advisory Committee on Immunization Practices ([ACIP](#)) and approved by the Centers for Disease Control and Prevention ([CDC](#)), American Academy of Pediatrics ([AAP](#)), American Academy of Family Physicians ([AAFP](#)), American College of Obstetricians and Gynecologists ([ACOG](#)), American College of Nurse-Midwives ([ACNM](#)), American Academy of Physician Associates ([AAPA](#)), and National Association of Pediatric Nurse Practitioners ([NAPNAP](#)).

The comprehensive summary of the ACIP recommended changes made to the child and adolescent immunization schedule can be found in the [January 11, 2024 MMWR](#).

### Report

- Suspected cases of reportable vaccine-preventable diseases or outbreaks to your state or local health department
- Clinically significant adverse events to the Vaccine Adverse Event Reporting System (VAERS) at [www.vaers.hhs.gov](http://www.vaers.hhs.gov) or (800-822-7967)

### Questions or comments

Contact [www.cdc.gov/cdc-info](http://www.cdc.gov/cdc-info) or 800-CDC-INFO (800-232-4636), in English or Spanish, 8 a.m.–8 p.m. ET, Monday through Friday, excluding holidays.

### Helpful information

- [Complete Advisory Committee on Immunization Practices \(ACIP\) recommendations](#)
- [ACIP Shared Clinical Decision-Making Recommendations](#)
- [General Best Practice Guidelines for Immunization \(including contraindications and precautions\)](#)
- [Vaccine information statements](#)
- [Manual for the Surveillance of Vaccine-Preventable Diseases \(including case identification and outbreak response\)](#)

### SOURCES

**CONTENT SOURCE:**  
National Center for Immunization and Respiratory Diseases